Search

Displaying results 3081 - 3090 of 10000 in total
  1. Drug

    Turoctocog alfa

    go.drugbank.com/drugs/DB09109
    Approved

    [A31504] It was developped by Novo Nordisk and FDA approved in October 16, 2013.[L1104] … Turoctocog alfa is produced in Chinese hamster ovary (CHO) cells without addition of any human- or animal-derived materials.

  2. Drug

    Tositumomab

    go.drugbank.com/drugs/DB00081
    ApprovedWithdrawn

    It is produced in an antibiotic-free culture of mammalian cells. It can be covalently linked to Iodine 131 (a radioactive isotope of iodine).

  3. Drug

    Levobetaxolol

    go.drugbank.com/drugs/DB09351
    Approved

    Levobetaxolol is a beta-blocker used to lower the pressure in the eye to treat conditions such as glaucoma.

  4. Drug

    Bethanechol

    go.drugbank.com/drugs/DB01019
    Approved

    Bethanechol is a synthetic ester that was initially synthesized in 1935. … An advantage of bethanechol is that in contrast to acetylcholine, bethanechol is not degraded by cholinesterase allowing its effects to be longer-lasting.[L32539]

    Synonyms: 2-(carbamoyloxy)-N,N,N-trimethylpropan-1-aminium
  5. Drug

    Nilotinib

    go.drugbank.com/drugs/DB04868
    ApprovedInvestigational

    A Phase I clinical trial in 2006 showed that this drug was relatively safe and offered significant therapeutic benefits in cases of CML which were found to be resistant to treatment with imatinib (Gleevec

  6. Drug

    Moclobemide

    go.drugbank.com/drugs/DB01171
    ApprovedInvestigational

    Most meta-analyses and most studies indicate that in the acute management of depression, moclobemide is more efficacious than placebo medication and similarly efficacious as tricyclic antidepressants (

    Synonyms: 4-Chlor-N-(2-morpholinoethyl)benzamid, p-Chloro-N-(2-morpholinoethyl)benzamide
  7. Drug

    CX501

    go.drugbank.com/drugs/DB05174
    Investigational

    It is developed by Cellerix and is in phase I of clinical trials. … Cx501 is used to treat epidermolysis bullosa (EB), a rare genetic condition which can lead to contraction of the joints, fusion of fingers and toes, contraction of the mouth membranes and narrowing of

  8. Drug

    NS-2359

    go.drugbank.com/drugs/DB05805
    Investigational

    This mode of action is expected to produce an optimal reduction in all disease symptoms and the possibility of an earlier onset of action compared to antidepressants already on the market.

  9. Drug

    Dermatophagoides farinae

    go.drugbank.com/drugs/DB10400
    ApprovedInvestigational

    Dermatophagoides farinae extracts are sterile solutions used for intradermal testing or subcutaneous immunotherapy. This combination is approved for as a year-round, once-a-day tablet that's dissolved under the tongue as a treatment for ...

  10. Drug

    Tocilizumab

    go.drugbank.com/drugs/DB06273
    ApprovedInvestigational

    [L43697] After being investigated to treat severely ill patients with COVID-19,[A193278,L12837,L12843] tocilizumab was approved by the European Commission in December 2021 to treat COVID-19 in adults receiving … [L12789] It was first described in the literature in 2003 when Chugai, a subsidiary of Roche began developing IL-6 inhibiting monoclonal antibodies.

    Products: ACTEMRA (162 MG SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE), ACTEMRA 162MG/0.9ML SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE